

GSK Worldwide

GSK

GSK: A leading biopharma company

GSK: a focused biopharma company, with expertise in developing innovative specialty medicines and vaccines.

Leading portfolio of vaccines, specialty and general medicines.

Almost 70,000 people and a presence in more than 75 countries worldwide.

Innovation powered by £6.6 billion R&D investment in 2025.

- 58 medicines and vaccines in development.
 - 17 assets in phase III / registration
 - 5 major product approvals in 2025.
-





Our purpose

We unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of **2.5 billion people** by the end of the decade.

Our portfolio

Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. Alongside current growth drivers, our R&D is focused on 14 scale opportunities launching between 2025 and 2031.

Specialty Medicines

Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer.

1st

to pioneer HIV treatments in 1980 and leaders in HIV innovation

50 years

helping millions of people with respiratory conditions to breathe more easily

80%

of our revenue growth in 2024 generated by specialty medicines

Vaccines

Our broad vaccines portfolio targets infectious disease at every stage of life, helping to protect people from meningitis, shingles, RSV, flu, polio and many more.

20+

vaccines in our portfolio

>1m

vaccine doses delivered each day

General Medicines

From antibiotics to inhaled medicines for asthma and COPD, we have a broad portfolio of general medicine products, many of them market leaders, making life better for millions of people worldwide.

100+

countries are supplied with GSK products

Vaccines at a glance

We have more than
20 vaccines
to help protect people
from a range of diseases
throughout their lives



We supply vaccines to
people living in over
160 countries



About
2,000 scientists
work in vaccine R&D



We have
**17 vaccine
candidates**
in our pipeline as we
seek to develop new vaccines
against
infectious diseases¹



Our vaccines portfolio

More than
20 vaccines
to help protect
people at all
stages of life



Paediatric

Diphtheria
Haemophilus influenzae type b (Hib)
Hepatitis A
Hepatitis B
Influenza (seasonal flu)
Measles
Meningococcal
Mumps
Pertussis
Pneumococcal
Poliomyelitis
Rotavirus
Rubella
Tetanus
Varicella



Adults and travel

Cervical cancer (HPV)
Diphtheria
Hepatitis A
Hepatitis B
Influenza (seasonal flu)
Measles
Meningococcal
Mumps
Pertussis
Poliomyelitis
Rubella
Shingles
Tetanus
Varicella
RSV



Older adults

Diphtheria
Hepatitis A
Hepatitis B
Influenza (seasonal flu)
Pertussis
Shingles
Tetanus
RSV